DiaSorin (DSRLF) Projected to Post Quarterly Earnings on Thursday

DiaSorin (OTCMKTS:DSRLF) is projected to post its results on Thursday, November 12th. Analysts expect the company to post earnings of $2.46 per share and revenue of $341.81 million for the quarter.

DiaSorin Stock Performance

OTCMKTS DSRLF opened at $92.00 on Wednesday. The firm’s 50 day moving average is $87.32 and its 200-day moving average is $79.91. DiaSorin has a 12-month low of $66.50 and a 12-month high of $92.00.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Zacks Research upgraded shares of DiaSorin from a “strong sell” rating to a “hold” rating in a research note on Friday, October 2nd. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of DiaSorin in a research report on Tuesday, August 4th. Finally, UBS Group downgraded DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, August 12th. Two research analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, DiaSorin has a consensus rating of “Strong Sell”.

DiaSorin Company Profile

DiaSorin is an Italian diagnostics company that develops and markets in vitro diagnostic tests and instruments for clinical laboratories and hospitals. Its products support the detection and monitoring of a range of conditions, including infectious diseases, hormonal disorders, and autoimmune and metabolic conditions. The company’s portfolio includes immunodiagnostic assays and molecular diagnostic tests, along with laboratory platforms such as its LIAISON systems. These products are designed to help laboratories conduct testing across multiple areas of clinical care.